ALKERMES | ALKS - Capital Ordinário

Preço das Ações
33.31
Mudança Diária
-0.60 -1.77%
Mensal
13.42%
Anual
19.65%
Q2 Previsão
32.32




Capital Ordinário Alterar Data
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
ALKERMES USD 165.61M 503K 2025-12
Amgen USD 539M 1000K 2025-12
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 946.83M 354.23M 2025-06
Gilead Sciences USD 1.24B 1000K 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
J&J USD 2.41B 1.74M 2025-12
Malin Corporation EUR 200K 0 2024-12
Merck USD 2.49B 15.79M 2025-09
Minerva Neurosciences USD 1000 0 2024-09
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.1M 400K 2025-12
Otsuka Holdings JPY 528.13M 0 2025-12
Ovoca Bio EUR 29.49M 18.43M 2025-06
Pfizer USD 5.69B 1000K 2025-09
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Vertex Pharmaceuticals USD 254M 0 2025-12